Showing 8231-8240 of 20875 results for "".
Do We Need to Temper our Enthusiasm for Incretin-Based Therapy?
https://reachmd.com/programs/diabetes-discourse/do-we-need-to-temper-our-enthusiasm-for-incretin-based-therapy/5947/There have been impressive results with incretin-based therapy for patients with type 2 diabetes: improved A1C, beta-cell preservation and weight loss are some of the benefits. But do healthcare professionals need to temper their enthusiasm for this novel therapy? Join host Dr. Steven Edelman and hiGFAP and VEGF Trajectories in Adult Type 3 Spinal Muscular Atrophy Under Nusinersen
https://reachmd.com/programs/neurofrontiers/gfap-and-vegf-trajectories-in-adult-type-3-spinal-muscular-atrophy-under-nusinersen/54637/Closing Gaps in Care for Patients with T2D & CV Disease
https://reachmd.com/programs/diabetes-discourse/closing-gaps-in-care-for-patients-with-t2d-cv-disease/15148/Learn more about obstacles to care for patients with type 2 diabetes and cardiovascular disease from the recent COORDINATE study.Sexual Dysfunction: Communication is the Key
https://reachmd.com/programs/diabetes-discourse/sexual-dysfunction-communication-is-the-key/4603/A certified diabetes educator can help both physicians and patients when it comes to sexual dysfunction. Sexual dysfunction is experienced by over half of all women with diabetes, and approximately 32 percent of men with type 1 and 46 percent of men with type 2. So, it is critical to provide good coManaging Obesity & Pre-Diabetes When Lifestyle Modifications Fail
https://reachmd.com/programs/primary-care-today/managing-obesity-pre-diabetes-when-lifestyle-modifications-fail/7818/What options are available to our patients at risk of diabetes after other modifications fall short of target goals?New Developments in Incretins and SGLT Inhibitors
https://reachmd.com/programs/diabetes-discourse/new-developments-in-incretins-and-sglt-inhibitors/4694/The physiological effects of glucagon-like peptide-1 (GLP-1) are exciting because of the potential clinical relevance in treating two of the major abnormalities that contribute to type 2 diabetes: impaired insulin secretion and excessive glucagon secretion. GLP-1 also appears to have effects on gastSurvodutide in Obesity: Insights from SYNCHRONIZE-1
https://reachmd.com/programs/clinicians-roundtable/survodutide-obesity-synchronize-1/57029/New findings from the SYNCHRONIZE-1 trial reveal that survodutide's impact extends beyond weight reduction, with a demonstrated decrease in liver fat and meaningful improvements across multiple markers of metabolic health in patients without type 2 diabetes. Dr. Carel le Roux joins us to share the eDiabetes Highlights from ENDO 2013 - the 95th Annual Meeting of The Endocrine Society
https://reachmd.com/programs/conference-coverage/diabetes-highlights-from-endo-2013-the-95th-annual-meeting-of-the-endocrine-society/6823/Diabetes Highlights from ENDO, the 95th Annual Meeting of The Endocrine Society. The Endocrine Society is the world's oldest, largest, and most active organization devoted to research on hormones and the clinical practice of endocrinology. In this program, you will hear from global thought leadersTwo Types of Tax-Advantaged Benefit Plans: Why Aesthetic Practices Should Consider Both
https://reachmd.com/topics/practice-development/two-types-of-tax-advantaged-benefit-plans-why-aesthetic-practices-should-consider-both/35155/A look at ways to reduce taxes an increase retirement savingsCan Autologous Stem Cells Reverse the Damage of a Heart Attack?
https://reachmd.com/programs/heart-matters/can-autologous-stem-cells-reverse-the-damage-of-a-heart-attack/5258/Stem cell therapies across multiple disciplines continue to demonstrate promising results. How successful are autologous cardiac stem cell treatments proving to be at regenerating cardiac tissue after a heart attack? Which patients would be the best candidates for this procedure, and when might this